Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.

Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS.

Br J Haematol. 2018 Dec 21. doi: 10.1111/bjh.15720. [Epub ahead of print]

PMID:
30575016
2.

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, Salles G.

J Clin Oncol. 2019 Jan 10;37(2):144-152. doi: 10.1200/JCO.18.00400. Epub 2018 Nov 27.

PMID:
30481079
3.

Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.

Mackrides N, Chapman J, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt O, Syrbu S, Ansell SM, Habermann TM, Link BK, Feldman AL, Lossos IS, Cerhan JR, Vega F.

Am J Hematol. 2019 Feb;94(2):E62-E64. doi: 10.1002/ajh.25357. Epub 2018 Dec 5. No abstract available.

PMID:
30474261
4.

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

Han JJ, O'byrne M, Stenson MJ, Maurer MJ, Wellik LE, Feldman AL, McPhail ED, Witzig TE, Gupta M.

Blood Cancer J. 2018 Nov 12;8(11):110. doi: 10.1038/s41408-018-0138-8.

6.

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.

Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR, Braggio E, Maurer MJ, Feldman AL, Witzig TE, Slager SL, Ansell SM, Cerhan JR, Novak AJ.

Blood Cancer J. 2018 Oct 9;8(10):97. doi: 10.1038/s41408-018-0130-3.

7.

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani-Baiti NN, Thompson CA, Cerhan JR, Witzig TE.

Nutr Cancer. 2018 Sep 20:1-3. doi: 10.1080/01635581.2018.1502328. [Epub ahead of print]

PMID:
30235018
8.

The association of physical activity before and after lymphoma diagnosis with survival outcomes.

Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA.

Am J Hematol. 2018 Dec;93(12):1543-1550. doi: 10.1002/ajh.25288. Epub 2018 Oct 17.

PMID:
30230581
9.

History of autoimmune conditions and lymphoma prognosis.

Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR.

Blood Cancer J. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4.

10.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

11.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.

Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.

PMID:
29897404
12.

Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, Inwards DJ, Macon WR, Link BK, Rosenthal AC, Cerhan JR.

Hematol Oncol. 2018 Dec;36(5):749-756. doi: 10.1002/hon.2522. Epub 2018 Jun 3.

PMID:
29862550
13.

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT.

Br J Haematol. 2018 Sep;182(5):644-653. doi: 10.1111/bjh.15416. Epub 2018 May 29.

PMID:
29808922
14.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

PMID:
29788332
15.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.

J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.

PMID:
29672223
16.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G.

Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.

PMID:
29666118
17.

Online Physician Reviews Do Not Reflect Patient Satisfaction Survey Responses.

Widmer RJ, Maurer MJ, Nayar VR, Aase LA, Wald JT, Kotsenas AL, Timimi FK, Harper CM, Pruthi S.

Mayo Clin Proc. 2018 Apr;93(4):453-457. doi: 10.1016/j.mayocp.2018.01.021.

18.

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV.

Blood Cancer J. 2018 Feb 28;8(3):26. doi: 10.1038/s41408-018-0065-8.

19.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.

Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.

PMID:
29477102
20.

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.

Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell SM, Thompson CA, Weiner GJ, Nowakowski GS, Allmer C, Slager SL, Witzig TE, Cerhan JR, Link BK.

Haematologica. 2018 Feb;103(2):297-303. doi: 10.3324/haematol.2017.176511. Epub 2017 Nov 23.

21.

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL.

J Clin Oncol. 2017 Dec 20;35(36):4019-4026. doi: 10.1200/JCO.2017.73.8195. Epub 2017 Oct 26.

22.

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE.

Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. doi: 10.1093/ije/dyx119. No abstract available.

23.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

PMID:
28961306
24.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR.

Blood Cancer J. 2017 Aug 25;7(8):e595. doi: 10.1038/bcj.2017.70.

25.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.

Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588.

26.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES.

Genes Cancer. 2017 May;8(5-6):589-599. doi: 10.18632/genesandcancer.142.

27.

Variability of performance status assessment between patients with hematologic malignancies and their physicians.

Leal AD, Allmer C, Maurer MJ, Shanafelt TD, Cerhan JR, Link BK, Thompson CA.

Leuk Lymphoma. 2018 Mar;59(3):695-701. doi: 10.1080/10428194.2017.1347930. Epub 2017 Jul 18.

PMID:
28718335
28.

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK.

Br J Haematol. 2017 Oct;179(1):50-60. doi: 10.1111/bjh.14813. Epub 2017 Jun 27.

29.

Transthoracic Echocardiography versus Computed Tomography for Ascending Aortic Measurements in Patients with Bicuspid Aortic Valve.

Park JY, Foley TA, Bonnichsen CR, Maurer MJ, Goergen KM, Nkomo VT, Enriquez-Sarano M, Williamson EE, Michelena HI.

J Am Soc Echocardiogr. 2017 Jul;30(7):625-635. doi: 10.1016/j.echo.2017.03.006. Epub 2017 May 10.

PMID:
28501375
30.

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma.

Manso BA, Wenzl K, Asmann YW, Maurer MJ, Manske M, Yang ZZ, Slager SL, Nowakowski GS, Ansell SM, Witzig TE, Feldman AL, Rimsza L, Link B, Cerhan JR, Novak AJ.

Blood Cancer J. 2017 Apr 21;7(4):e553. doi: 10.1038/bcj.2017.33. No abstract available.

31.

Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma.

Binder M, O'Byrne MM, Maurer MJ, Ansell S, Feldman AL, Cerhan J, Novak A, Porrata LF, Markovic S, Link BK, Witzig TE.

Am J Hematol. 2017 Aug;92(8):752-758. doi: 10.1002/ajh.24758. Epub 2017 Jun 1.

32.

Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.

Pham AQ, Broski SM, Habermann TM, Jevremovic D, Wiseman GA, Feldman AL, Maurer MJ, Ristow KM, Witzig TE.

Leuk Lymphoma. 2017 Oct;58(10):2342-2348. doi: 10.1080/10428194.2017.1300891. Epub 2017 Mar 14.

PMID:
28290723
33.

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.

Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, Cliby WA, Oberg AL, Kaufmann SH, Goode EL.

Clin Cancer Res. 2017 Aug 1;23(15):4077-4085. doi: 10.1158/1078-0432.CCR-17-0246. Epub 2017 Mar 9.

34.

Metabolic engineering of a haploid strain derived from a triploid industrial yeast for producing cellulosic ethanol.

Kim SR, Skerker JM, Kong II, Kim H, Maurer MJ, Zhang GC, Peng D, Wei N, Arkin AP, Jin YS.

Metab Eng. 2017 Mar;40:176-185. doi: 10.1016/j.ymben.2017.02.006. Epub 2017 Feb 16.

PMID:
28216106
35.

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J.

Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3.

36.

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia.

Sfeir JG, Drake MT, LaPlant BR, Maurer MJ, Link BK, Berndt TJ, Shanafelt TD, Cerhan JR, Habermann TM, Feldman AL, Witzig T.

Blood Cancer J. 2017 Feb 3;7(2):e526. doi: 10.1038/bcj.2017.9. No abstract available.

37.

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Labouré G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link BK, Tarte K, Witzig TE, Lamy T, Slager SL, Roussel M, Milpied N, Cerhan JR, Fest T.

Leukemia. 2017 Apr;31(4):988-991. doi: 10.1038/leu.2016.385. Epub 2017 Jan 27. No abstract available.

38.

Quantitative Trait Loci (QTL)-Guided Metabolic Engineering of a Complex Trait.

Maurer MJ, Sutardja L, Pinel D, Bauer S, Muehlbauer AL, Ames TD, Skerker JM, Arkin AP.

ACS Synth Biol. 2017 Mar 17;6(3):566-581. doi: 10.1021/acssynbio.6b00264. Epub 2016 Dec 28.

39.

Sex Differences and Survival in Adults With Bicuspid Aortic Valves: Verification in 3 Contemporary Echocardiographic Cohorts.

Michelena HI, Suri RM, Katan O, Eleid MF, Clavel MA, Maurer MJ, Pellikka PA, Mahoney D, Enriquez-Sarano M.

J Am Heart Assoc. 2016 Sep 29;5(10). pii: e004211.

40.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

41.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK.

Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492. Epub 2016 Sep 3.

42.

A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.

Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, Salles G.

Br J Haematol. 2018 Jan;180(2):286-290. doi: 10.1111/bjh.14306. Epub 2016 Sep 9. No abstract available.

43.

Brain potentials predict substance abuse treatment completion in a prison sample.

Fink BC, Steele VR, Maurer MJ, Fede SJ, Calhoun VD, Kiehl KA.

Brain Behav. 2016 May 31;6(8):e00501. doi: 10.1002/brb3.501. eCollection 2016 Aug.

44.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.

45.

Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast.

Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S.

G3 (Bethesda). 2016 Jul 7;6(7):1853-66. doi: 10.1534/g3.116.027953.

46.

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.

Parry HM, Damery S, Hudson C, Maurer MJ, Cerhan JR, Pachnio A, Begum J, Slager SL, Fegan C, Man S, Pepper C, Shanafelt TD, Pratt G, Moss PA.

Am J Hematol. 2016 Aug;91(8):776-81. doi: 10.1002/ajh.24403. Epub 2016 Jun 1.

47.

Gene Amplification on Demand Accelerates Cellobiose Utilization in Engineered Saccharomyces cerevisiae.

Oh EJ, Skerker JM, Kim SR, Wei N, Turner TL, Maurer MJ, Arkin AP, Jin YS.

Appl Environ Microbiol. 2016 May 31;82(12):3631-3639. doi: 10.1128/AEM.00410-16. Print 2016 Jun 15.

48.

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson BD, Brown WL, Kalli KR, Kaufmann SH, Harris RS.

Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910. Epub 2016 Mar 25.

49.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223. Epub 2015 Nov 26.

50.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE.

Ann Oncol. 2016 Jan;27(1):165-72. doi: 10.1093/annonc/mdv486. Epub 2015 Oct 20.

Supplemental Content

Loading ...
Support Center